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Abbreviations : 
TKI  : Tyrosine kinase inhibitor 
mCRC  : Metastatic colorectal cancer. 
CTCAE : Common toxicity criteria for Adverse Events 
ALT  : Alanine aminotransferase. 
AST  : Aspartate aminotransferase. 
LFT  : Liver function tests 
CYP3A4 : Cytochrome P 3A4. 
UGT1A9 : Uridine diphosphate-glucuronosyltransferase 1A9. 
GGT  : Gamma-glutamyltranspeptidase.  
ALP  : Alkaline phosphatase. 
LDH  : Lactate dehydrogenase. 
INR  : International normalized ratio. 
IHC  : Immunohistochemical 
HEV  : Hepatitis E virus 
DILI  : Drug-induced liver injury. 
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ABSTRACT   
BACKGROUND: Regorafenib is the first small-molecule multikinase inhibitor which 
showed survival benefits in pretreated metastatic colorectal cancer (mCRC) patients. Beside 
classical adverse events of this drug class, hepatotoxicity has been described as a frequent 
side effect. 
MATERIAL AND METHODS: Patients with refractory mCRC treated with regorafenib in 
our institution were reviewed. Severe treatment-related liver toxicity was investigated. 
Clinical history, liver histology and genetic assessment (sequence analysis) of cytochrome P 
3A4 (CYP3A4) and uridine diphosphate-glucuronosyltransferase 1A9 (UGT1A9) involved in 
regorafenib metabolization were here reported for patients with severe hepatotoxicity. 
RESULTS: Among the 93 reviewed patients, 3 presented severe and icteric toxic hepatitis 
which was fatal for 1 patient. Histopathological liver lesions were different depending on the 
onset of hepatotoxicity (acute or subacute): acinar zone 3 necrosis in case of acute symptoms 
and portal tract inflammation with porto-central bridging and fibrosis in the delayed 
presentation. None patients had CYP3A4 gene mutations. Similar polymorphisms in 
UGT1A9 gene promoter region (UGT1A9 variant –118T9>10 (rs3832043)) were found in both 
patients who presented acute hepatitis. Moreover, it appears retrospectively that both of them 
already experienced significant toxicity under irinotecan-based chemotherapy. 
CONCLUSION: This is the first report of severe hepatotoxicity with available liver histology 
and genetic assessment of enzymes involved in regorafenib metabolization. This report also 
reminds the importance of a close liver tests monitoring during regorafenib treatment.  
 
KEY WORDS:  
Regorafenib – Metastatic colorectal cancer – Hepatotoxicity – Liver histology
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KEY POINTS 
- Regorafenib showed survival benefits in pretreated metastatic colorectal and is widely used. 
- Hepatotoxicy is a frequent side effect, severe liver injury is rare but grave.  
- Histopathological lesions of severe liver injury show acinar zone 3 necrosis in case of acute 
onset and portal tract inflammation with porto-central bridging and fibrosis in the delayed 
presentation. 
- Genetic assessment of UGT1A9 and CYP3A4 (gene involved in regorafenib 
metabolization) reveals similar polymorphisms in UGT1A9 gene promoter region (UGT1A9 
variant –118T9>10 (rs3832043)) associated with the acute form presentation.  
 
 BACKGROUND 
 Regorafenib is a novel orally administered tyrosine kinase inhibitor (TKI) targeting 
different protein kinases associated with angiogenesis, oncogenesis and maintenance of the 
tumor microenvironment. It showed survival benefits in pretreated metastatic colorectal 
cancer (mCRC) patients. In 2013, based on results of phase III trial CORRECT [1], 
regorafenib gained approval by the European Medicines Agency for pretreated mCRC 
patients. 
 
Beside classical adverse events (fatigue, hypertension, hand-foot skin reaction and 
diarrhea), hepatotoxicity has been described as a side effect. In the CORRECT study, 
Common Toxicity Criteria (4.0) for Adverse Event (CTCAE) grade ≥3 hyperbilirubinemia 
was observed in 2% patients, and no other adverse events associated with liver dysfunction 
were reported. In the CONCUR study (Asian population only), liver dysfunction was more 
frequent with grade ≥3 hyperbilirubinemia, alanine aminotransferase (ALT) and aspartate 
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aminotransferase (AST) elevation of 7%, 7% and 6% respectively [2].  As the mechanism of 
this liver toxicity remains unclear, we focused here on hepatotoxicity occurring during 
regorafenib treatment to extensively characterize severe case of patients with liver injury.  
 
MATERIAL AND METHODS 
 Patients with refractory mCRC treated with regorafenib (160 mg/day 3 weeks on each 
4 week cycle) in the Cliniques Universitaires Saint-Luc between January 2011 and June 2015 
were reviewed. All these patients gave their consent to be treated in clinical trial [1] or in 
early access program before regorafenib was accessible in Belgium. Our objective was to 
describe the occurrence of severe treatment-related liver toxicity defined by at least an 
increase of bilirubin and ALT / AST to a grade 3 or 4 (CTCAE v4.0). We report here the 
detailed clinical history, liver function tests (LFT) and liver histology (biopsy) of identified 
patients. Given the hepatic metabolism of regorafenib via cytochrome P 3A4 (CYP3A4) and 
uridine diphosphate-glucuronosyltransferase 1A9 (UGT1A9), the most frequent mutations in 
both genes assessed by sequence analysis were also analyzed and reported. Approval for this 
research was obtained from the ethic committees of the Cliniques Universitaires Saint-Luc 
 
RESULTS 
Among the 93 patients treated with regorafenib, transient CTCAE grade 1-2 
hyperbilirubinemia, ALT and AST elevation were observed during the first 2 cycles (2 
months) in 21 patients (22.5%), 10 patients (10.7%) and 11 patients (11.8%) respectively. All 
patients had normal LFT (bilirubin, ALT and AST) before treatment. 
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Three patients (3.2%) presented severe toxic hepatitis (CTCAE grade 3-4 bilirubin, 
AST and ALT elevation):   
- Patient 1, a 66 year-old Caucasian female, has been treated with successive 
treatments, including irinotecan, oxaliplatin, fluoropyrimidine, bevacizumab, panitumumab 
and cetuximab for mCRC with lungs, left adrenal gland and right kidney metastases. She 
received. Regorafenib (160 mg/day) was prescribed after disease progression. LFT were 
normal at the beginning of the treatment. However, 2 weeks after starting regorafenib, the 
patient presented with fatigue, anorexia and jaundice. Blood test revealed elevated liver 
enzymes: ALT 3209 U/l (N <50), AST 2379 U/l (N <50), gamma-glutamyltranspeptidase 
(GGT) 251 U/l (N <50), alkaline phosphatase (ALP) 234 U/L (N 30–120), and lactate 
dehydrogenase (LDH) 841U/L (N <248) and total bilirubin 8.4 mg/dl (N 0.3–1.2). Except 
regorafenib, she was not taking any other drug. Viral and autoimmune serologies were 
negative (Supplementary Table 1). Liver ultrasound examination was normal. Regorafenib 
was definitely withdrawn and LFT gradually decreased up to normal range after 5 weeks. No 
liver biopsy was performed. Patient died from progressive tumoral disease 10 months after 
fully recovered of this toxic hepatitis. 
 - Patient 2 was a 68 year-old Caucasian male who has been treated for KRAS mutated 
mCRC with peritoneal carcinomatosis. After failure of FOLFOX (folinic acid, fluorouracil, 
oxaliplatin) and FOLFIRI (folinic acid, fluorouracil, irinotecan) – bevacizumab, a third line 
therapy with regorafenib (160 mg/day) was initiated. LFT were normal before starting 
regorafenib. Two weeks after starting treatment, the patient developed cutaneous jaundice, 
dark urine, anorexia and changes in sleep patterns. LFT were dosed: ALT 3268 U/l (N <50), 
AST 3599 U/l (N <50), GGT 187 U/l (N <50), ALP 294 U/L (N 30–120), LDH 947 U/L (N 
<248) and total bilirubin 19.0 mg/dl (N 0.3–1.2). International normalized ratio (INR) was 
4.48 (N 0.8-1.3), factor V 25% (N 70-140), albumin 3g/dl (N3.5-5.2), blood glucose 97mg/dl 
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(N 70-110). Other daily medications were simvastatin, bisoprolol, apixaban and lisinopril, all 
of these having been introduced more than 6 months ago. Regorafenib and all other 
treatments were stopped. Viral and auto-immune serological tests were negative except for a 
low non-specific antinuclear antibody positivity in the absence of IgG increase 
(Supplementary Table 1). Liver ultrasound did not detect the presence of hepatic metastases, 
nor biliary obstruction. In the context of acute hepatitis, high dose intravenous acetylcysteine 
was initiated. Corticotherapy was also given for 8 days. Although regorafenib was promptly 
withdrawn, LFT kept worsening (week 2: bilirubin 35.4 mg/dl, INR 3.3), leading to 
progressive worsening of encephalopathy and fatal liver failure 5 weeks after treatment 
initiation. A postmortem percutaneous liver biopsy was performed. Histology showed 
centrilobular hepatic necrosis with confluent destruction of acinar zones 3. Portal tracts areas 
were preserved and inflammation was scarce (Fig. 1A). Immunohistochemical (IHC) and 
molecular tests were negative for hepatitis E virus (HEV) (Supplementary Table 2) 
 - Patient 3, a 68-year old Caucasian female, was suffering from KRAS mutated 
mCRC with lung and liver metastases. She had been successively treated with capecitabine-
oxaliplatine – bevacizumab and FOLFIRI. Regorafenib was initiated at full dose. LFT were 
normal at the beginning of treatment. Due to significant asthenia and anorexia, the dosage 
was reduced to 120 mg per day from the second cycle. After 2 months, a radiologic 
evaluation showed a stable disease. After 4 months of treatment, elevated LFT were found on 
routine blood test: ALT 1738 U/l (N <50), AST 1347 U/l (N <50), GGT 624 U/l (N <50), 
ALP 296 U/L (N 30–120), LDH 482U/L (N <248) and total bilirubin 5.2 mg/dl (N 0.3–1.2). 
Autoimmune and viral serologies were negative (Supplementary Table 1). No others 
hepatotoxic drugs were taken.  Regorafenib was withdrawn and high dose intravenous 
acetylcysteine was administered. A transjugular liver biopsy was performed. The 
hepatovenous gradient was 4 mmHg. Liver histology showed severe portal tract inflammation 
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with porto-central bridging, fibrosis and hepatocytes loss in the central area (Fig. 1B). IHC 
and molecular testings were negative for HEV (Supplementary Table 2). LFT progressively 
improved with normalisation within 2 months after stopping the treatment. Patient died from 
progressive tumoral disease 6 months after fully recovered of this complication. 
 Given the hepatic metabolism of regorafenib via CYP3A4 and UGT1A9, the most 
frequent mutations in both 2 genes were assessed by sequence analysis. Patient 1 and patient 
2 carried similar genetic polymorphisms in the UGT1A9 gene promoter region. Both were 
heterozygous for UGT1A9*22 allele (UGT1A29 variant –118T9>10; rs3832043), 
characterized by a single base insertion of thymidine. Moreover, a heterogenous and 
homogenous intronic transversion (C>T) were identified in patients 1 and 2 respectively. 
UGT1A9 sequencing did not show any mutation in patient 3. Regarding the CYP3A4 gene, 
no mutation was discovered in any of the patients. 
 Patients’ characteristics are summarized in Table 1. 
 
DISCUSSION 
   
The introduction of small-molecule TKIs in clinical oncology has transformed the 
treatment of certain forms of cancers. Unexpectedly, their use has been found to be associated 
with serious toxic effects on a number of vital organs including the liver.  Indeed, 
hepatotoxicity in cancer patients treated with TKI is well reported and justifies close 
monitoring: a meta-analysis demonstrated a significant increase of developing high-grade 
hepatotoxicity with TKIs use [3-4].  
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 The regorafenib safety profiles were initially limited before investigators decided to 
proceed to a phase III trial due to positive signals observed in phase I [5]. Although less 
predictable, elevated LFT were also frequent and generally occurred soon after treatment 
initiation. Therefore, monitoring of bilirubin and transaminases was considered as crucial 
during the first two cycles in order to allow early discontinuation in case of liver 
abnormalities. Severe drug-induced liver injury (DILI) led to fatal outcome in only 0.3% of 
1100 regorafenib-treated patients across all clinical trials [6] and all patients presenting with 
hepatic failure also had liver metastases.  
 
 In our trial, the proportion of patients with grade 1-2 increased bilirubin or 
aminotransferases was higher as reported in the CORRECT trial [1]. Here, we reported 
severe hepatoxicity for 3 patients including one patient with fatal outcome. We distinguish 
two clinical histories of hepatitis, each of them associated with different histopathological 
patterns. In patient 3, biochemical abnormalities and symptoms appeared several months after 
initiation of the treatment, and liver biopsy showed features of severe active hepatitis with 
portal inflammation, bridging fibrosis, reminding of auto-immune hepatitis. By contrast, in 
patient 2, we found centrilobular necrosis, a morphological abnormality seen in acute 
acetaminophen toxicity, whose mechanism is also linked to the P-450 cytochrome system.  
 
 Regorafenib is a major substrate of CYP3A4, a factor described as an important 
predictor of DILI [7]. Furthermore, given its exclusive liver metabolism, regorafenib is a 
medication at higher risk for DILI [8]. In the patient 2 case, regorafenib was coadministred 
with three other CYP3A4 substrates (simvastatin, bisoprolol and apixaban) but all of them 
were already introduced since several months. Considering that more than one substrate can 
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bind to the active enzyme site of CYP3A4 [9] and the clear evidence for cooperativity in 
substrate binding and in catalytic turnover [10], the influence of other CYP3A4 substrates on 
regorafenib metabolism could have been a factor contributing to the severe toxicity observed 
in patient 2.  
 UGT1A9 is the second enzyme implicated in regorafenib metabolism. Over the last 
decade, polymorphism in UGT1A superfamily has been widely studied, particularly in order 
to predict interindividual toxicity of irinotecan [11]. Moreover, a recent Chinese study 
showed an association between UGT1A9 promoter polymorphisms (T>C transition; 
position−440 (rs2741045)) and DILI [12] but no pieces of evidence demonstrated so far the 
functional impact of -118T9>10 polymorphism on interindividual variation in hepatic 
UGT1A9 activity and mRNA expression [13]. In the present report, it is of note that both 
patients presenting with acute hepatic dysfunction exhibited similar polymorphisms (variant –
118T9>10) in UGT1A9 gene promoter region. Retrospectively, it appears that both of them 
experienced intolerance under irinotecan-based chemotherapy requiring fast dose reduction: 
grade 3 neutropenia during the first cycle for patient 1 and grade 3 neutropenia and diarrhea 
for patient 2.  
Our report remains descriptive with several limitations that cannot confirm the definitive role 
of UGT1A9 polymorphisms in regorafenib hepatotoxicity (and a possible cross-toxicity with 
irinotecan). Indeed, UGT1A9 genotyping was only performed in the 3 patients with severe 
liver injury and not in the remaining cohort. Moreover, the reported high frequency (up to 
39% of patients) and lack of interindividual liver activity variation of the -118T9>10 
polymorphism justifies caution and further reports before any conclusion. 
Another limitation is the absence of histology available for patient 1. However, acute 
presentation following regorafenib introduction and return to normal after treatment cessation 
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are in favor of DILI. HEV is a relevant differential diagnosis to DILI. Since patient’s residual 
sera were not available, we applied combined IHC and molecular testing for HEV on liver 
biopsies and found no evidence for a HEV infection (Supplementary Table 2).  
 To our knowledge, this is the first report of severe hepatotoxicity with available liver 
histology and genetic assessment of enzymes involved in regorafenib metabolization. 
Conversely to the published case-reports [14-16], one of our patients died from liver failure. 
LFT from others patients improved with normalisation as described in these reports. 
Furthermore, our patients had no previous history of liver dysfunction. Both of these 
arguments advocate a direct toxicity of the multikinase inhibitor without predisposing liver 
condition. 
 In summary, this report highlights the importance of a close liver monitoring during 
regorafenib treatment, especially during the first cycles. Nevertheless, even if infrequent, 
delayed hepatic toxicity can occur. It illustrates also that severe hepatotoxicity is not limited 
to patients presenting with liver metastases. Whereas the mechanism of toxicity remains so 
far unclear, further reports are needed to explore the role of CYP3A4 and UGT1A9 
polymorphisms and hepatic activities and the possible cross-toxicity with irinotecan...  
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Figure legends 
 
Fig. 1A: Post mortem liver biopsy from patient 2, hematoxylin-eosin, original magnification 
X8. There is extensive necrosis around the central vein (*) with confluent destruction of 
acinar zones 3 (arrow heads). By contrast, the portal tracts (PT) areas are mostly preserved. 
 
Fig. 1B: Transjugular liver biopsy from patient 3, Masson’s Trichrome, original 
magnification X12. Severe portal tract inflammation together with interface hepatitis and 
porto-central bridging is observed (arrow). Centrolobular areas (upper left) show 
inflammation and hepatocytes loss. 
  
 
Table 1: Patient’s characteritics 
 
 Patient 1 Patient 2 Patient 3 
Age and sex 66-year old female 68-year old male 68-year old female 
KRAS mutation 
(exon 2) 
Absence Presence Presence 
Presence of liver 
metastases 
No No Yes 
Toxicity under 
FOLFIRI 
Grade III 
neutropenia during 
first cycle 
Grade III 
neutropenia and 
diarrhoea 
No 
Time between start 
regorafenib and 
hepatotoxicity 
2 weeks 2 weeks 4 months 
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